|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2011-1-12
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
To confirm the efficacy, tolerability, and safety of NGX-4010, an 8% capsaicin dermal patch (capsaicin 640 µg/cm(2) ), in patients with postherpetic neuralgia (PHN). PHN is a chronic pain disorder that can be difficult to treat and for which current treatment options are often limited by poor tolerability.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1526-4637
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Wiley Periodicals, Inc.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
99-109
|
|
pubmed:meshHeading |
pubmed-meshheading:21087403-Administration, Topical,
pubmed-meshheading:21087403-Aged,
pubmed-meshheading:21087403-Analgesics,
pubmed-meshheading:21087403-Capsaicin,
pubmed-meshheading:21087403-Dose-Response Relationship, Drug,
pubmed-meshheading:21087403-Double-Blind Method,
pubmed-meshheading:21087403-Endpoint Determination,
pubmed-meshheading:21087403-Female,
pubmed-meshheading:21087403-Humans,
pubmed-meshheading:21087403-Male,
pubmed-meshheading:21087403-Neuralgia, Postherpetic,
pubmed-meshheading:21087403-Pain Measurement,
pubmed-meshheading:21087403-Socioeconomic Factors,
pubmed-meshheading:21087403-Transdermal Patch,
pubmed-meshheading:21087403-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia.
|
|
pubmed:affiliation |
Swedish Pain Center, Seattle, Washington, USA.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
